Anisha B. Dua, MD, MPH
Professor of Medicine
Northwestern University
Chicago, Illinois
Dr. Anisha B. Dua is a Professor of Medicine, Rheumatology Fellowship Program Director and Director of the Vasculitis Center at Northwestern University Feinberg School of Medicine. Her interests are in rheumatology education and vasculitis. She has completed fellowships in Rheumatology at Rush, Medical Education at The University of Chicago, and Integrative Medicine at Northwestern. Dr. Dua currently leads a multidisciplinary team in the clinical management of vasculitis patients. She assisted in the development of the American College of Rheumatology/Vasculitis Foundation Guideline for the Treatment and Management of Vasculitis and is on the Board of Directors for the Vasculitis Foundation and the Rheumatology Research Foundation. She is a recipient of the Clinical Scholar Educator award from the Rheumatology Research Foundation and Chair of the ACR Committee on Training. She has served in multiple leadership roles both locally and nationally through the American College of Rheumatology, the Vasculitis Foundation, and the ACGME in the areas of education as well as vasculitis.
Jason M. Springer, MD
Associate Professor Chair, Vanderbilt Vasculitis Center
Vanderbilt University Medical Center
Nashville, Tennessee
Dr. Jason Springer completed a general rheumatology fellowship and vasculitis fellowship at Cleveland Clinic. He served as director of the vasculitis center at University of Kansas for seven years. Afterwards, he moved to Vanderbilt University Medical Center where he is codirector of the Vanderbilt Vasculitis Center. He served on the Board of Directors for the Vasculitis Foundation for six years. He has active research studies in the fields of anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis, Takayasu arteritis, and giant cell arteritis.
The faculty have the following relevant financial relationships with ineligible companies:
Michael E. Wechsler, MD, MMSc: Consulting Fees: Allakos, Amgen, Areteia Therapeutics, Arrowhead Pharmaceutical, AstraZeneca, Avalo Therapeutics, Belenos Bio, Celldex, Connect Biopharma, Eli Lilly, Equillium, Glaxosmithkline, Incyte, Jasper Therapeutics, Kinaset, Kymera, Merck, MyBiometry, Pharming, Phylaxis, Pulmatrix, Rapt Therapeutics, recludix Pharma, Roche/Genentech, Regeneron, Sanofi/ Genzyme, Sentien, Sound Biologics, Tetherex Pharmaceuticals, Uniquity Bio, Upstream Bio, Verona Pharma, Zurabio; Stock Options: Upstream Bio
Praveen Akuthota, MD: Consulting Fees: Amgen, AstraZeneca, Connect Biopharma, Enveda, GlaxoSmithKline, Sanofi; Contracted Research: AstraZeneca, Sanofi
Anisha B. Dua, MD, MPH: Consulting Fees: Amgen, Abbvie, Astra Zeneca, Sanofi, GSK, Novartis; Contracted Research: Amgen Novartis
Jason M. Springer, MD: Consulting Fees: Acepodia, Clinical Trial Services, Neovii, NS Pharma, Zenas; Steering Committee: Neovii
The planners and managers have no relevant financial relationships with ineligible companies.
DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Integritas does not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
FEE INFORMATION & REFUND/ CANCELLATION POLICY
There is no fee for this activity.
AMERICANS WITH DISABILITIES
Any activity registrant who feels s/he may need accommodation based on the impact of a disability should contact Integritas Communications at info@exchangecme.com to discuss their specific needs.
CONTACT INFORMATION
For information about this program, please contact us at info@exchangecme.com.
CLINICAL PRACTICE GUIDELINES
» 2021 American College of Rheumatology (ACR)/ Vasculitis Foundation guideline for the management of antineutrophil cytoplasmic antibody– associated vasculitis.
Chung SA, et al. Arthritis Rheumatol. 2021;73(8):1366-1383. https://acrjournals.onlinelibrary.wiley.com/doi/10.1002/art.41773
» 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology (EULAR) classification criteria for eosinophilic granulomatosis with polyangiitis.
Grayson PC, et al. Ann Rheum Dis. 2022;81(3):309-314. https://ard.eular.org/article/S0003-4967(24)09565-7/abstract
» EULAR recommendations for the management of ANCA- associated vasculitis: 2022 update.
Hellmich B, et al. Ann Rheum Dis. 2024;83(1):30-47. https://ard.bmj.com/content/83/1/30
SUGGESTED READING
» Evidence-Based Guideline for the diagnosis and management of eosinophilic granulomatosis with polyangiitis.
Emmi G., et al. Nat Rev Rheumatol. 2023;19(6):378-393. https://www.nature.com/articles/s41584-023-00958-w
» The five-factor score revisited: assessment of prognoses of systemic necrotizing vasculitides based on the French Vasculitis Study Group (FVSG) cohort.
Guillevin L, et al. Medicine. 2011;90(1):19-27. https://journals.lww.com/md-journal/fulltext/2011/01000/the_five_factor_score_ revisited__assessment_of.2.aspx
» Benralizumab as a steroid-sparing treatment option in eosinophilic granulomatosis with polyangiitis.
Gunter VP, et al. J Allergy Clin Immunol Pract. 2021;9(3):1186-1193.e1. https://www.jaci-inpractice.org/article/S2213-2198(20)31104-1/abstract
» Eosinophilic granulomatosis with polyangiitis: latest findings and updated treatment recommendations.
Watanabe R and Hashimoto M. J Clin Med. 2023;12(18):5996. https://www.mdpi.com/2077-0383/12/18/5996
» Benralizumab versus mepolizumab for eosinophilic granulomatosis with polyangiitis.
Wechsler ME, et al. N Engl J Med. 2024;90(10):911-921.
https://www.nejm.org/doi/10.1056/NEJMoa2311155?url_ver=Z39.88-2003&rfr_ id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed
» Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis.
Wechsler ME, et al. N Engl J Med. 2017;376(20):1921-1932.
https://www.nejm.org/doi/10.1056/NEJMoa1702079?url_ver=Z39.88-2003&rfr_ id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200www.ncbi.nlm.nih.gov
PATIENT ADVOCACY ORGANIZATIONS AND RESOURCES
» American College of Rheumatology (ACR)
ACR is a global medical society that serves physicians, health professionals, and scientists worldwide with the goal of advancing research and training to improve the health of people with rheumatic diseases.
https://rheumatology.org/
» American Thoracic Society (ATS)
The mission of the ATS is to improve health worldwide by advancing research, clinical care, and public health in respiratory disease, critical illness, and sleep disorders.
https://www.thoracic.org/patients/patient-resources/
» European Alliance of Associations for Rheumatology (EULAR)
EULAR represents people with rheumatic and musculoskeletal diseases, health professionals in rheumatology, rheumatologists, researchers and scientific societies in the field of rheumatology of all the European nations.
https://www.eular.org/
» Vasculitis Foundation
The mission of the Vasculitis Foundation is to build upon the collective strength of the vasculitis community, the Foundation supports, to inspire and empower individuals with vasculitis and their families through a wide range of education, research, clinical, and awareness initiatives.
https://vasculitisfoundation.org/
